Immune Checkpoint Inhibitors (ICIs), a new generation of anti-cancer drugs, liberate the immune system enabling it to destroy tumorous growths by inhibiting negative costimulatory molecules like cytotoxic T lymphocyte-associated protein-4 (CTLA-4) and programmed death receptors (PD-1/PD-L1). The gene discussed is CD274; the disease is cancer.